Revance Therapeutics Inc. (NASDAQ:RVNC) shares shot up 5.9% on Thursday . The stock traded as high as $14.66 and last traded at $14.61, with a volume of 71,008 shares. The stock had previously closed at $13.79.

Several research firms have recently weighed in on RVNC. Piper Jaffray Cos. restated an “overweight” rating and set a $35.00 price objective (down from $54.00) on shares of Revance Therapeutics in a research note on Tuesday, June 14th. SunTrust Banks Inc. lowered their price objective on shares of Revance Therapeutics from $46.00 to $22.00 and set a “buy” rating on the stock in a research note on Tuesday, June 14th. Zacks Investment Research upgraded shares of Revance Therapeutics from a “hold” rating to a “buy” rating and set a $15.00 price objective on the stock in a research note on Wednesday, July 13th. Guggenheim restated a “buy” rating and set a $55.00 price objective on shares of Revance Therapeutics in a research note on Tuesday, June 14th. Finally, Brean Capital restated a “hold” rating on shares of Revance Therapeutics in a research note on Friday, August 5th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $39.60.

The company has a 50 day moving average of $13.60 and a 200 day moving average of $17.10. The company’s market capitalization is $424.13 million.

Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by $0.02. The business had revenue of $0.80 million for the quarter, compared to analysts’ expectations of $0.06 million. The business’s revenue for the quarter was up .0% compared to the same quarter last year. On average, analysts forecast that Revance Therapeutics Inc. will post ($3.53) earnings per share for the current fiscal year.

An institutional investor recently bought a new position in Revance Therapeutics stock. Russell Frank Co acquired a new position in shares of Revance Therapeutics Inc. (NASDAQ:RVNC) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 38,974 shares of the biopharmaceutical company’s stock, valued at approximately $1,384,000. Russell Frank Co owned 0.14% of Revance Therapeutics as of its most recent SEC filing.

Revance Therapeutics, Inc is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.